There will be no third act for Endo's pain drug partnership with Grunenthal. Endo had originally signed on to the pact in early 2009, gaining U.S. marketing rights to axomadol. But earlier this summer investigators reported the disappointing news that the drug had failed a mid-stage study, and this morning the biotech company said it will shutter the program and dump the collaboration. Story